NCT02720263View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 28, 2016

Primary Completion Date

June 8, 2017

Study Completion Date

June 8, 2017

Conditions
Schizophrenia
Interventions
DRUG

ASP4345

Oral

DRUG

Matching Placebo

Oral

Trial Locations (1)

91206

Site US10001, Glendale

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02720263 - A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter